Biocon Limited informed on Monday that its subsidiary Biocon Biologics announced the US market availability of YESINTEK ...

Biocon Biologics has launched YESINTEK, a biosimilar to Stelara, in the United States for treating chronic autoimmune ...

Indian benchmark indices Nifty 50 and Sensex ended the previous trade session in the red. Nifty 50 closed at 22,552.50, while ...

Three ustekinumab biosimilars enter the US market, expanding access to more affordable options referencing Stelara ...

The company, along with its subsidiary NTPC Green Energy, has entered into multiple MoUs with the Madhya Pradesh government ...

NTPC along with its arm NTPC Green Energy signed multiple MoUs with Madhya Pradesh government to invest over Rs 2 lakh crore ...

Johnson & Johnson (NYSE:JNJ) is reportedly suing Samsung Bioepis for breach of contract related to the launch of a biosimilar ...

A number of stocks are set to be in focus during the coming session on Dalal Street, including NTPC, NTPC Green, SBI Card and ...

The vaccine contract manufacturing market is expanding rapidly, driven by rising global demand for immunization and a growing emphasis on preventive healthcare. Biobanks play a crucial role by ...

The NSE Nifty 50 ended 1.06% lower at 22,553.35, while the BSE Sensex closed 1.14% down at 74,454.41 on Monday.

Shares of firms like Biocon, LIC, NTPC Green, IREDA, Texmaco Rail, and others will be in focus on Tuesday's trade ...

YESINTEK is approved for Crohn's disease, ulcerative colitis, plaque psoriasis, and psoriatic arthritis, offering a ...